Thursday, July 23, 2020 11:30:11 AM
But Abbvie has managed to make Humira the biggest drug ever with multiple indications and accounts for 60%+ of their business.
They competed the acquisition of Allergan this year to offset the revenue stream losses they expect when Humira loses its protection and generics come online.
The migraine space now has multiple MABs that have helped people go from 20+ migraine days a month to less than 10,5, or none on some cases.
MABs are definitely a large part of future therapeutic treatments. The biggest aversion is people who don’t want to get a shot every month.
One migraine MAB actually has a 90 day version now so people only have to get an injection every 3 months and only have to go to the Dr every 3 months for it.
All just food for thought.
HGEN ????
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM